Login to Change.org
Create an Account
Jessica Pickett
Recent Activity
-
Jessica commented on the article |
Anyone who is interested in this job should definitely check out last week's interview with a health policy analyst, which is very applicable to this organization and position.
-
Jessica commented on the article |I love love love this post.
-
Jessica commented on the article |When I told my mom that I was planning to pursue a graduate degree in international health policy, she asked if that meant that I would be taking more biology classes.
-
Jessica commented on the article |I've asked "do you have any concerns about my candidacy that I can use this opportunity to address?" In my case, I think it really made the difference - I stiffen up during interviews and had come across as overly formal, so that allowed me to persuade them that yes, I would be a good personality fit.
One quibble: for Washington-based policy positions, it's definitely standard for junior staff to stay 1-2 years at most (at least for their first job). In really small nonprofits or think tanks, there is just limited room for internal advancement; moreover, many young people move on to grad school around that point in their career. So in those situations, a more appropriate follow-up question would be "what types of positions/grad programs are typical of your junior staff 'alumni'?"
-
Jessica commented on the article |Check out Scott Barrett's latest article on polio eradication in this month's issue of Health Affairs.
-
Jessica commented on the article |Loren, I 100% agree - in fact, not focusing on the management aspect was an oversight on my part. I've been very lucky so far in having incredibly supportive bosses, and it makes all the world of difference.
-
Jessica commented on the article |I completely agree on the health costs of unnecessary injections. However, I do think that in some places, the problem is as much about demand as supply. In parts of rural India, for example, many patients prefer injections to oral remedies, and have come to expect a shot to signal that the medical transaction is complete. So in addition to changing provider behavior, we also need to better educate patients.
-
Jessica commented on the article |You should check out CGD's ongoing Drug Resistance Working Group at www.cgdev.org/drug_resistance for an analysis of the underlying international policy dilemmas and ideas for potential solutions. A consultation draft report with the group's preliminary recommendations should be available soon.
-
Jessica commented on the article |Karen: On your latter point that short-term donations may be an appropriate response (not just a bandaid), I'm not entirely sure I agree. Yes, it is definitely true that heavy product subsidies may be necessary to eliminate a disease, or even to control it indefinitely - see Kremer & Miguel's work on the "Illusion of Sustainability" on the externalities issues, for example - but I think that in most cases would be somewhat preferable to have those subsidies footed by a neutral third party donor (with purely financial support from companies), who would compensate the pharma companies for the costs of manufacture. The advantage of this approach is two-fold: first, it would presumably be easier to integrate the drugs into the existing health system through the regular government procurement and distribution process, and second, it would allow generic manufacturers to compete for part of the market-share. Of course, this makes my own point about the best being the enemy of the good, since the incentives are such that this approach would in reality just decrease the total available resources.
-
Jessica commented on the article |WHO just issued a related report on the impact of the financial crisis on global health: http://www.who.int/mediacentre/events/meetings/2009_financial_crisis_report_en_.pdf.
Impact
0 Actions
0 Recruits